Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 15/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 15/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 11/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 11/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28112588 | 0.80 | KCNQ3 (0.44) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL27833168 | 0.77 | ALDH1A1 (0.43) | ALDH1A1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL27649577 | 0.76 | ALDH1A1 (0.41) | KCNQ3KCNQ2KCNE1KCNQ1ALDH1A1 | |
| SCHEMBL5460611 | 0.75 | ALDH1A1 (0.41) | ALDH1A1LMNA | |
| SCHEMBL2323497 | 0.75 | FDFT1 (0.47) | ALDH1A1LMNA | |
| SCHEMBL82306 | 0.75 | LMNA (0.43) | KCNQ3KCNQ2ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL12922670 | 0.75 | KCNQ3 (0.42) | KCNQ3KCNQ2ALDH1A1LMNA | |
| SCHEMBL7195937 | 0.75 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL31003562 | 0.75 | LMNA (0.43) | KCNQ3KCNQ2ALDH1A1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27945887 | 0.75 | ALDH1A1 (0.41) | ALDH1A1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686196-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | Hangzhou Innogate Pharma Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| CN-106414448-B | It can be used as the new compound of S100- inhibitor | 活跃生物技术有限公司 | 2019-04-19 | — | — | CN | disclosed |
| CN-108349996-A | Tricyclic PI3K inhibitor compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2018-07-31 | — | — | CN | disclosed |
| EP-2402341-B1 | Purinyl derivatives and their use as potassium channel modulators | SANIONA AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| EP-2402341-B1 | Purinyl derivatives and their use as potassium channel modulators | SANIONA AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| EP-2142546-B1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | SANIONA AS (DK) | 2017-06-07 | — | — | EP | disclosed |
| EP-2142546-B1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | SANIONA AS (DK) | 2017-06-07 | — | — | EP | disclosed |
| CN-106794181-A | MTH1 inhibitors for the treatment of inflammatory and autoimmune conditions | 托马斯·黑勒戴药物研究基金会 | 2017-05-31 | — | — | CN | disclosed |
| US-9340544-B2 | Purinyl derivatives and their use as potassium channel modulators | ATAXION, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340544-B2 | Purinyl derivatives and their use as potassium channel modulators | ATAXION, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | disclosed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | disclosed |
| CN-101646669-A | Purinyl derivatives and their use as potassium channel modulators | NEUROSEARCH AS DK | 2010-02-10 | — | — | CN | disclosed |
| WO-2009156336-A1 | SULFOXIMINAMIDE COMPOUNDS FOR COMBATING ANIMAL PESTS | BASF SE (DE) | 2009-12-30 | — | — | WO | disclosed |
| US-20090163464-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2008116909-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20060058320-A1 | [1,2,4] Triazolo[1,5-c]pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
| EP-1544200-A1 | 1,2,4 -TRIAZOLO 1,5-c PYRIMIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058320-A1 | [1,2,4] Triazolo[1,5-c]pyrimidine derivatives | ADORA2A, ADORA1, ADORA3 | KCNQ3 698/4885KCNQ2 808/4885KCNE1 734/4885 |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | KCNQ3 30/4885KCNQ2 10/4885KCNE1 36/4885 |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | KCNQ3 4820/4885KCNQ2 4674/4885KCNE1 3848/4885 |
| US-20090163464-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | HRH2, HRH1, HRH4 | KCNQ3 960/4885KCNQ2 1785/4885KCNE1 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.